Our results obtained in a cell culture model of deep intrinsic resistance, featuring highly adaptable TNBC cells that opportunistically switch between quiescence and proliferation, suggest that the BET bromodomain inhibitor JQ1 may be useful for sensitizing resistant breast cancer cells at the MRD stage in patients with breast cancer at high risk of recurrence. This evidence concerns the gene DNER and breast carcinoma.